JP2022017221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022017221A5 JP2022017221A5 JP2021145986A JP2021145986A JP2022017221A5 JP 2022017221 A5 JP2022017221 A5 JP 2022017221A5 JP 2021145986 A JP2021145986 A JP 2021145986A JP 2021145986 A JP2021145986 A JP 2021145986A JP 2022017221 A5 JP2022017221 A5 JP 2022017221A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- compound according
- acceptable salt
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 110
- 150000001875 compounds Chemical class 0.000 claims 101
- 150000003839 salts Chemical class 0.000 claims 88
- 125000005843 halogen group Chemical group 0.000 claims 40
- 125000003118 aryl group Chemical group 0.000 claims 32
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 31
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 26
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 23
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 22
- 229910052799 carbon Inorganic materials 0.000 claims 21
- 125000004432 carbon atom Chemical group C* 0.000 claims 19
- 125000001424 substituent group Chemical group 0.000 claims 19
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 6
- 125000006713 (C5-C10) cycloalkyl group Chemical group 0.000 claims 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 5
- 125000006193 alkinyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- -1 SCH 3 Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 101000735473 Homo sapiens Protein mono-ADP-ribosyltransferase TIPARP Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100034905 Protein mono-ADP-ribosyltransferase TIPARP Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664544P | 2018-04-30 | 2018-04-30 | |
| US62/664,544 | 2018-04-30 | ||
| JP2020560916A JP6942896B2 (ja) | 2018-04-30 | 2019-04-29 | Ｐａｒｐ７阻害剤としてのピリダジノン |
| PCT/US2019/029582 WO2019212937A1 (en) | 2018-04-30 | 2019-04-29 | Pyridazinones as parp7 inhibitors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560916A Division JP6942896B2 (ja) | 2018-04-30 | 2019-04-29 | Ｐａｒｐ７阻害剤としてのピリダジノン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022017221A JP2022017221A (ja) | 2022-01-25 |
| JP2022017221A5 true JP2022017221A5 (enExample) | 2022-06-10 |
| JP7518049B2 JP7518049B2 (ja) | 2024-07-17 |
Family
ID=66476851
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560916A Active JP6942896B2 (ja) | 2018-04-30 | 2019-04-29 | Ｐａｒｐ７阻害剤としてのピリダジノン |
| JP2021145986A Active JP7518049B2 (ja) | 2018-04-30 | 2021-09-08 | Ｐａｒｐ７阻害剤としてのピリダジノン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560916A Active JP6942896B2 (ja) | 2018-04-30 | 2019-04-29 | Ｐａｒｐ７阻害剤としてのピリダジノン |
Country Status (36)
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11293927B2 (en) | 2018-04-30 | 2022-04-05 | Ribon Therapeutics, Inc. | Screening methods for PARP modulators |
| HRP20230458T1 (hr) * | 2018-04-30 | 2023-07-21 | Ribon Therapeutics Inc. | Piridazinoni kao inhibitori parp7 |
| US11512090B2 (en) | 2018-06-11 | 2022-11-29 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| CA3108076A1 (en) | 2018-09-04 | 2020-03-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine m1 receptor antagonists |
| SG11202109568TA (en) * | 2019-03-20 | 2021-10-28 | Goldfinch Bio Inc | Pyridazinones and methods of use thereof |
| US12371421B2 (en) | 2019-04-29 | 2025-07-29 | Ribon Therapeutics, Inc. | Solid forms of a PARP7 inhibitor |
| IL291951A (en) * | 2019-10-07 | 2022-06-01 | Pipeline Therapeutics Inc | Muscarinic m1 acetylcholine receptor antagonists |
| US20240190844A1 (en) * | 2019-10-30 | 2024-06-13 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
| CN114761086B (zh) * | 2019-10-30 | 2025-07-22 | 里邦医疗公司 | 作为parp7抑制剂的哒嗪酮 |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| WO2021216898A1 (en) * | 2020-04-23 | 2021-10-28 | Plexxikon Inc. | Compounds and methods for cd73 modulation and indications therefor |
| EP4161923A4 (en) * | 2020-06-09 | 2023-10-11 | Relive Therapeutics Inc. | Compounds comprising a three ring core as pd-1/pd-l1 blockers |
| US20230257382A1 (en) * | 2020-07-03 | 2023-08-17 | Wuhan Ll Science And Technology Development Co., Ltd. | Heterocyclic compound and use thereof |
| WO2022111700A1 (zh) * | 2020-11-27 | 2022-06-02 | 成都百裕制药股份有限公司 | 哒嗪酮衍生物及其在医药上的应用 |
| JP7623826B2 (ja) * | 2020-12-18 | 2025-01-29 | 株式会社 資生堂 | Ｔｉｐａｒｐ産生促進剤 |
| WO2022156708A1 (en) * | 2021-01-20 | 2022-07-28 | Jacobio Pharmaceuticals Co., Ltd. | Parp7 enzyme inhibitor |
| EP4289845A4 (en) * | 2021-02-03 | 2025-01-08 | Shanghai Apeiron Therapeutics Company Limited | Triheterocyclic compound, preparation method therefor, and application thereof |
| CN114907408B (zh) * | 2021-02-07 | 2024-05-03 | 武汉朗来科技发展有限公司 | 一种杂环化合物、其中间体、其制备方法及其应用 |
| BR112023015721A2 (pt) * | 2021-02-09 | 2023-11-07 | Jacobio Pharmaceuticals Co Ltd | Derivados tricíclicos úteis como inibidores de parp7 |
| US20220265654A1 (en) * | 2021-02-16 | 2022-08-25 | Ribon Therapeutics, Inc. | Dosage regimens for parp7 inhibitors |
| CN115028648B (zh) * | 2021-03-03 | 2024-08-30 | 武汉誉祥医药科技有限公司 | 三并环化合物及其药物组合物和应用 |
| CN117425648A (zh) * | 2021-03-12 | 2024-01-19 | 杭州英创医药科技有限公司 | 作为parp7抑制剂的化合物 |
| TW202246274A (zh) * | 2021-03-16 | 2022-12-01 | 大陸商上海翰森生物醫藥科技有限公司 | 含氮雜環的多環化合物及其製備方法和應用 |
| CA3211149A1 (en) | 2021-03-31 | 2022-10-06 | Phillip Martin Cowley | Pharmaceutical compound |
| GB202114315D0 (en) * | 2021-10-06 | 2021-11-17 | Duke Street Bio Ltd | Pharmaceutical compound |
| CN117083274A (zh) * | 2021-04-23 | 2023-11-17 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| WO2022242750A1 (zh) * | 2021-05-21 | 2022-11-24 | 成都百裕制药股份有限公司 | 哌嗪衍生物及其在医药上的应用 |
| WO2022247839A1 (zh) * | 2021-05-25 | 2022-12-01 | 山东轩竹医药科技有限公司 | Parp7抑制剂 |
| CN115477640A (zh) * | 2021-05-31 | 2022-12-16 | 由理生物医药（上海）有限公司 | 作为parp7抑制剂的哒嗪酮类化合物 |
| CN117751108A (zh) * | 2021-07-21 | 2024-03-22 | 南京明德新药研发有限公司 | 哒嗪酮类化合物 |
| WO2023001296A1 (zh) * | 2021-07-23 | 2023-01-26 | 武汉人福创新药物研发中心有限公司 | 作为parp7抑制剂的哒嗪酮类化合物 |
| CN117279907A (zh) * | 2021-08-06 | 2023-12-22 | 成都百裕制药股份有限公司 | 吡咯烷酮衍生物及其在医药上的应用 |
| WO2023020479A1 (zh) * | 2021-08-16 | 2023-02-23 | 重庆华森制药股份有限公司 | Parp7抑制剂及其应用 |
| EP4387966A1 (en) * | 2021-08-17 | 2024-06-26 | InventisBio Co., Ltd. | Pyridazinone or pyridinone compounds, preparation methods and uses thereof |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| CN115745971B (zh) * | 2021-12-20 | 2024-07-30 | 北京华森英诺生物科技有限公司 | Parp7抑制剂及其应用 |
| CN116375688B (zh) * | 2021-12-23 | 2025-04-11 | 中国药科大学 | 哒嗪酮类化合物及其制备方法、药物组合物和应用 |
| CN116444497B (zh) * | 2022-01-14 | 2025-06-24 | 如东凌达生物医药科技有限公司 | 一类哒嗪酮类化合物、制备及其应用 |
| WO2023143236A1 (zh) * | 2022-01-26 | 2023-08-03 | 中国药科大学 | 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用 |
| CN116535395B (zh) * | 2022-01-26 | 2024-07-09 | 中国药科大学 | 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4338737A4 (en) * | 2022-04-01 | 2024-11-06 | Novostar Pharmaceuticals, Ltd. | PARP7 INHIBITOR AND ITS USE |
| TW202346294A (zh) * | 2022-04-21 | 2023-12-01 | 大陸商四川海思科製藥有限公司 | 吡嗪酮衍生物及其在醫藥上的應用 |
| CN117586263A (zh) * | 2022-08-09 | 2024-02-23 | 成都百裕制药股份有限公司 | 哌嗪衍生物及其在医药上的应用 |
| KR20250044422A (ko) * | 2022-08-09 | 2025-03-31 | 캉바이다 (시추안) 바이오테크놀로지 씨오. 엘티디. | 종양 치료를 위한 방사선요법과 병용한 피페라진 화합물의 용도 |
| JP2025526003A (ja) * | 2022-08-09 | 2025-08-07 | 康百達（四川）生物医薬科技有限公司 | ピペラジン化合物とｐｄ－１阻害剤またはｐｄ－ｌ１阻害剤との組成物、および腫瘍治療におけるその使用 |
| CN119731176A (zh) * | 2022-08-17 | 2025-03-28 | 北京加科思新药研发有限公司 | 化合物i或其盐的固体形式 |
| GB202213819D0 (en) | 2022-09-22 | 2022-11-09 | Duke Street Bio Ltd | Pharmaceutical compound |
| CN115490671B (zh) * | 2022-10-21 | 2024-05-14 | 水木未来(北京)科技有限公司 | Parp7抑制剂及其制备方法 |
| JP2025536416A (ja) * | 2022-11-14 | 2025-11-05 | 康百達（四川）生物医薬科技有限公司 | 置換ピペラジン誘導体の結晶およびその調製方法 |
| GB202217888D0 (en) | 2022-11-29 | 2023-01-11 | Duke Street Bio Ltd | Pharmaceutical compound |
| CN120513238A (zh) * | 2023-01-06 | 2025-08-19 | 齐鲁制药有限公司 | 一种parp7抑制剂的制备方法 |
| WO2024149234A1 (en) * | 2023-01-10 | 2024-07-18 | Angel Pharmaceutical Co., Ltd. | Parp7 inhibitors and uses thereof |
| CN120917010A (zh) * | 2023-01-10 | 2025-11-07 | 嘉兴和剂药业有限公司 | Parp7抑制剂及其用途 |
| CN118388414A (zh) * | 2023-01-17 | 2024-07-26 | 中国药科大学 | 哒嗪酮类化合物及其制备方法、药物组合物和应用 |
| WO2025036478A1 (zh) * | 2023-08-17 | 2025-02-20 | 康百达（四川）生物医药科技有限公司 | 一种哌嗪衍生物的药物制剂、其制备方法及其用途 |
| TW202511263A (zh) * | 2023-08-29 | 2025-03-16 | 大陸商康百達（四川）生物醫藥科技有限公司 | 一種呱嗪衍生物的製備方法及其中間體 |
| WO2025087383A1 (zh) * | 2023-10-26 | 2025-05-01 | 深圳众格生物科技有限公司 | 作为parp7抑制剂的化合物 |
| TW202519233A (zh) * | 2023-11-13 | 2025-05-16 | 大陸商康百達（四川）生物醫藥科技有限公司 | 一種parp7抑制劑聯合用藥的藥物組合及其治療腫瘤的用途 |
| CN117342983B (zh) * | 2023-12-05 | 2024-02-06 | 康羽生命科学技术(苏州)有限公司 | 过乙酰化GalNAc-L96合成方法 |
| WO2025209574A1 (zh) * | 2024-04-03 | 2025-10-09 | 康百达（四川）生物医药科技有限公司 | 用于预防或治疗肿瘤的parp7抑制剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999013332A1 (en) | 1997-09-05 | 1999-03-18 | Matsushita Electric Industrial Co., Ltd. | Fluorescence polarization method |
| WO2002082082A2 (en) | 2001-04-09 | 2002-10-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorescence polarization assay |
| HU227237B1 (en) * | 2001-09-27 | 2010-12-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them |
| GB0301628D0 (en) | 2002-09-19 | 2003-02-26 | Aventis Pharma Inc | Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP) |
| CN1976906B (zh) * | 2004-06-30 | 2010-09-01 | 詹森药业有限公司 | 用作parp抑制剂的取代2-烷基喹唑啉酮衍生物 |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| JP5335675B2 (ja) | 2006-07-25 | 2013-11-06 | セファロン、インク． | ピリジジノン誘導体 |
| KR101641596B1 (ko) * | 2007-11-15 | 2016-07-21 | 엠에스디 이탈리아 에스.알.엘. | Ｐａｒｐ 억제제로서의 피리다지논 유도체 |
| JP5492183B2 (ja) * | 2008-03-27 | 2014-05-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびチューブリン重合阻害剤としてのテトラヒドロフェナントリジノンおよびテトラヒドロシクロペンタキノリノン |
| CA2771190C (en) * | 2009-08-17 | 2020-01-21 | Memorial Sloan-Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| CN103570725B (zh) * | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| WO2014143241A1 (en) * | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2016116602A1 (en) * | 2015-01-23 | 2016-07-28 | Astrazeneca Ab | Treatment of cancer |
| CN106749261A (zh) * | 2015-11-23 | 2017-05-31 | 中国科学院上海药物研究所 | 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途 |
| TWI785022B (zh) | 2017-03-28 | 2022-12-01 | 美商富曼西公司 | 新穎噠嗪酮類除草劑 |
| CA3075727A1 (en) * | 2017-09-18 | 2019-03-21 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| GB201717080D0 (en) | 2017-10-18 | 2017-11-29 | Syngenta Participations Ag | Chemical process |
| US11293927B2 (en) | 2018-04-30 | 2022-04-05 | Ribon Therapeutics, Inc. | Screening methods for PARP modulators |
| HRP20230458T1 (hr) | 2018-04-30 | 2023-07-21 | Ribon Therapeutics Inc. | Piridazinoni kao inhibitori parp7 |
| US12371421B2 (en) | 2019-04-29 | 2025-07-29 | Ribon Therapeutics, Inc. | Solid forms of a PARP7 inhibitor |
| US20240190844A1 (en) | 2019-10-30 | 2024-06-13 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
| CN114761086B (zh) | 2019-10-30 | 2025-07-22 | 里邦医疗公司 | 作为parp7抑制剂的哒嗪酮 |
-
2019
- 2019-04-29 HR HRP20230458TT patent/HRP20230458T1/hr unknown
- 2019-04-29 PL PL19723272.1T patent/PL3788040T3/pl unknown
- 2019-04-29 KR KR1020207034323A patent/KR102862474B1/ko active Active
- 2019-04-29 AR ARP190101124A patent/AR121419A1/es unknown
- 2019-04-29 PE PE2020001749A patent/PE20211382A1/es unknown
- 2019-04-29 DK DK19723272.1T patent/DK3788040T3/da active
- 2019-04-29 TW TW112127538A patent/TWI877697B/zh active
- 2019-04-29 RS RS20230450A patent/RS64283B1/sr unknown
- 2019-04-29 AU AU2019262927A patent/AU2019262927B2/en active Active
- 2019-04-29 US US16/397,103 patent/US10550105B2/en active Active
- 2019-04-29 JP JP2020560916A patent/JP6942896B2/ja active Active
- 2019-04-29 SI SI201930544T patent/SI3788040T1/sl unknown
- 2019-04-29 BR BR112020022006-0A patent/BR112020022006A2/pt unknown
- 2019-04-29 PT PT197232721T patent/PT3788040T/pt unknown
- 2019-04-29 SM SM20230172T patent/SMT202300172T1/it unknown
- 2019-04-29 LT LTEPPCT/US2019/029582T patent/LT3788040T/lt unknown
- 2019-04-29 CA CA3098585A patent/CA3098585A1/en active Pending
- 2019-04-29 CN CN201980044076.5A patent/CN112424188B/zh active Active
- 2019-04-29 SG SG11202010183XA patent/SG11202010183XA/en unknown
- 2019-04-29 IL IL278116A patent/IL278116B2/en unknown
- 2019-04-29 ES ES19723272T patent/ES2949538T3/es active Active
- 2019-04-29 MX MX2020011465A patent/MX2020011465A/es unknown
- 2019-04-29 EA EA202092590A patent/EA202092590A1/ru unknown
- 2019-04-29 EP EP23161423.1A patent/EP4234551A3/en active Pending
- 2019-04-29 MA MA52486A patent/MA52486B1/fr unknown
- 2019-04-29 WO PCT/US2019/029582 patent/WO2019212937A1/en not_active Ceased
- 2019-04-29 CN CN202510769671.2A patent/CN120987912A/zh active Pending
- 2019-04-29 FI FIEP19723272.1T patent/FI3788040T3/fi active
- 2019-04-29 MD MDE20210210T patent/MD3788040T2/ro unknown
- 2019-04-29 HU HUE19723272A patent/HUE062096T2/hu unknown
- 2019-04-29 IL IL308983A patent/IL308983B2/en unknown
- 2019-04-29 TW TW108114978A patent/TWI811353B/zh active
- 2019-04-29 CR CR20200518A patent/CR20200518A/es unknown
- 2019-04-29 EP EP19723272.1A patent/EP3788040B1/en active Active
- 2019-10-24 US US16/662,409 patent/US10870641B2/en active Active
-
2020
- 2020-08-11 US US16/990,677 patent/US11014913B2/en active Active
- 2020-10-21 ZA ZA2020/06549A patent/ZA202006549B/en unknown
- 2020-10-22 PH PH12020551760A patent/PH12020551760A1/en unknown
- 2020-10-29 CO CONC2020/0013599A patent/CO2020013599A2/es unknown
- 2020-10-29 MX MX2023005804A patent/MX2023005804A/es unknown
- 2020-10-29 CL CL2020002821A patent/CL2020002821A1/es unknown
- 2020-10-29 EC ECSENADI202069404A patent/ECSP20069404A/es unknown
-
2021
- 2021-04-12 US US17/227,705 patent/US11566020B1/en active Active
- 2021-09-08 JP JP2021145986A patent/JP7518049B2/ja active Active
-
2022
- 2022-10-27 US US17/974,830 patent/US20230192664A1/en not_active Abandoned
-
2023
- 2023-07-03 CY CY20231100310T patent/CY1126132T1/el unknown
-
2024
- 2024-01-30 AU AU2024200566A patent/AU2024200566A1/en active Pending
- 2024-03-22 US US18/613,601 patent/US20250034120A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022017221A5 (enExample) | ||
| KR100861486B1 (ko) | 퀴나졸린 유도체 | |
| JP5261575B2 (ja) | 化学化合物 | |
| US12351582B2 (en) | Aurora kinase inhibitors and uses thereof | |
| FI90980B (fi) | Menetelmä N-heterosyklisten N-(4-piperidyyli)-amidien valmistamiseksi | |
| JP2016053042A5 (enExample) | ||
| CA2802130A1 (en) | Cyanoquinoline derivatives | |
| US7501424B2 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| JP2023036991A (ja) | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法 | |
| EP3997086B1 (en) | Tetrahydroisoquinoline compounds | |
| JP2015518011A (ja) | ピロロ［２，１−ｆ］［１，２，４］トリアジン誘導体およびその抗腫瘍用途 | |
| US11548900B2 (en) | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | |
| JP5583201B2 (ja) | キノキサリン誘導体並びに良性の及び悪性の腫瘍疾患の治療のためのその使用 | |
| TWI343375B (en) | Indolinone derivatives, substituted in the 6-position, their preparation and their use as medicaments | |
| PL186851B1 (pl) | Pochodne piperazynodionu jako środki farmaceutyczne | |
| JP2007502308A (ja) | 置換チオフェンとその使用 | |
| JP3223193B2 (ja) | インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質 | |
| CN101171236A (zh) | 抗肿瘤的四氢嘧啶 | |
| EP4663628A1 (en) | New compound and pharmaceutical composition comprising same | |
| CN103554091B (zh) | 喹唑啉衍生物及其制备方法和用途 | |
| CN118974021A (zh) | 硫代苯并咪唑衍生物制备方法及用于其的新型中间体 | |
| KR20120047342A (ko) | 이마티닙의 신규 합성 방법 | |
| KR20050016946A (ko) | 아릴카보닐피페라진과 헤테로아릴카보닐피페라진 및 양성및 악성 종양 질환을 치료하기 위한 이들의 용도 |